PR94117

HYDERABAD, India and SHENZHEN, China, Jan. 19, 2022 /PRNewswire-=KYODO JBN/--

    Excelra, a leading global Data & Analytics organization, today announced

the partnership for its Global Online Structure Activity Relationship Database

(GOSTAR) with XtalPi Inc., an AI-based pharmaceutical biotechnology company

reinventing the industry's approach to drug research and development with its

Intelligent Digital Drug Discovery and Development platform.

    Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc.

as part of the partnership. GOSTAR's ADMET data will power XtalPi's predictive

models. The data helps XtalPi with high precision and predictability to

confidently tackle clinical failures of new chemical entities. The

well-annotated, high-quality ADMET datasets of GOSTAR are built with a

proprietary QMS-ISO certified curation process powered by NLP and human

intelligence.

    GOSTAR provides comprehensive information encompassing over 8 million

compounds, manually curated from a variety of sources including patents and

journal articles. The database contains over 29 million SAR associated data

points. The well-structured relational database can be utilized for diverse

applications across various stages of drug discovery and development lifecycle

and aids in target validation, hit identification, early lead identification,

and optimization.

    Min Xu, Senior Scientist, Research Manager, XtalPi Inc., said, "In XtalPi

Inc., we develop advanced AI-based algorithms to tackle the challenges in the

drug design process. The size and quality of datasets are always a big concern

for us to build high-accuracy predictive models. That is why we consider GOSTAR

as a unique and precious resource. It has millions of data points covering

different compounds' ADMET properties and is also trustful, structured, and

updated. We highly recommend GOSTAR to whoever is involved in the innovation of

drug design methodologies."

    Norman Azoulay, Product Leader, Excelra, said, "Artificial Intelligence and

Machine Learning is bringing a paradigm shift to drug discovery and

development. This partnership will help train XtalPi's models to accurately

predict efficacy and safety parameters and to ultimately increase the success

rate of drug design."

    About XtalPi:

    XtalPi is a pharmaceutical technology company that is reinventing the

industry's approach to drug research and development with its Intelligent

Digital Drug Discovery and Development platform. With tightly interwoven

quantum physics, artificial intelligence, and high-performance cloud computing

algorithms, XtalPi's platform provides accurate predictions on the

physiochemical and pharmaceutical properties of small-molecule candidates for

drug design, solid-form selection, and other critical aspects of drug

development. XtalPi is dedicated to improving the efficiency, accuracy, and

success rate of drug research and development, and contributing to a healthier

society worldwide. To know more, visit http://www.xtalpi.com.

    About Excelra:

    Excelra's data and analytics solutions empower innovation in life sciences

from molecule to market. The Excelra Edge comes from harmonizing heterogeneous

data sets, applying innovative bioinformatics know-how and technologies to

accelerate your drug discovery & development with reliable and result-oriented

insights. Excelra's GOSTAR is available as an application for users to seek,

find, and discover compounds. In addition, it is offered via APIs and as a

downloadable dataset to power in-house libraries and machine learning models.

    For more information about GOSTAR, visit www.gostardb.com  

    Logo: https://mma.prnewswire.com/media/692189/Excelra_Logo.jpg  

    SOURCE - Excelra Knowledge Solutions Pvt Ltd